TapewireFind a company

person · Reporting owner

Schneyer Mark C.

Disclosed activity across 1 company

Tapewire entity
25550
SEC CIK
0001899977

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACADIA PHARMACEUTICALS INCACAD · Entity 3913EVP, CHIEF FINANCIAL OFFICERAugust 05, 2026August 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date August 05, 2026 · Filed August 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect73,677 Reported balance After 2026-08-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-08-05 · Exercise / conversion · Acquired 5,849 · Balance 73,677

F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.

Common StockSEC Table I · non-derivativeDirect67,828 Reported balance After 2026-08-05 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-08-05 · Sale · Disposed 5,849 · Balance 67,828

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Common StockSEC Table I · non-derivativeDirect82,120 Reported balance After 2026-08-06 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2026-08-06 · Exercise / conversion · Acquired 14,292 · Balance 82,120

Common StockSEC Table I · non-derivativeDirect77,120 Reported balance After 2026-08-06 transaction · row 4 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 4 · 2026-08-06 · Sale · Disposed 5,000 · Balance 77,120

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

Common StockSEC Table I · non-derivativeDirect67,828 Reported balance After 2026-08-06 transaction · row 5 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 5 · 2026-08-06 · Sale · Disposed 9,292 · Balance 67,828

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24Direct74,715 Reported balance After 2026-08-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-08-05 · Exercise / conversion · Disposed 5,849 · Balance 74,715

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24Direct60,423 Reported balance After 2026-08-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-08-06 · Exercise / conversion · Disposed 14,292 · Balance 60,423

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 19, 2024 Filed Aug 20, 2024 22:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 9,733 $15.28 $148,720.24
Disclosure

SEC source: 0001415889-24-021731 · form4-08202024_100820.xml · nonDerivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,735

F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 22:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantCommon Stock 13,629 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-021731 · form4-08202024_100820.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,468

F2 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 22:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantCommon Stock 5,275 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-021731 · form4-08202024_100820.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,839

F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.

Read SEC document
June 10, 2024 Filed Jun 11, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 975 $14.79 $14,420.25
Disclosure

SEC source: 0001415889-24-016416 · form4-06112024_060601.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,564

F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.675 to $14.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
June 08, 2024 Filed Jun 11, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,893 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-016416 · form4-06112024_060601.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,893 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.

F5 · derivative.expiration_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.

Read SEC document
June 08, 2024 Filed Jun 11, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,893 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-016416 · form4-06112024_060601.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.

Read SEC document
May 02, 2024 Filed May 3, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 3,503 $16.94 $59,340.82
Disclosure

SEC source: 0001415889-24-012237 · form4-05032024_060510.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,053

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.94 to $17.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 6,814 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-012237 · form4-05032024_060510.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,445

Underlying: Common Stock · 6,814 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 6,814 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-012237 · form4-05032024_060510.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,556

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
April 08, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,716 $17.87 $48,534.92
Disclosure

SEC source: 0001415889-24-010601 · form4-04092024_060401.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,742

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7338 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 05, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 5,275 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-010601 · form4-04092024_060401.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,551

Underlying: Common Stock · 5,275 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 5,275 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-010601 · form4-04092024_060401.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,458

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 27, 2024 Filed Mar 27, 2024 23:57 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 5,434 $17.90 $97,268.60
Disclosure

SEC source: 0001415889-24-009270 · form4-03272024_110354.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,183

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 25, 2024 Filed Mar 27, 2024 23:57 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 24,714 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-009270 · form4-03272024_110354.xml · derivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,714

Underlying: Common Stock · 24,714 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Read SEC document
March 25, 2024 Filed Mar 27, 2024 23:57 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 80,564 $0.00 Strike: $17.84 $0.00
Disclosure

SEC source: 0001415889-24-009270 · form4-03272024_110354.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,564

Underlying: Common Stock · 80,564 shares

Expires 2034-03-24

F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
March 25, 2024 Filed Mar 27, 2024 23:57 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantCommon Stock 10,550 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-009270 · form4-03272024_110354.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,617

F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target

Read SEC document
February 26, 2024 Filed Feb 27, 2024 23:13 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 772 $24.67 $19,045.24
Disclosure

SEC source: 0001415889-24-005577 · form4-02272024_110237.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,067

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
February 23, 2024 Filed Feb 27, 2024 23:13 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,353 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-005577 · form4-02272024_110237.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,353

Underlying: Common Stock · 1,353 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 23:13 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,353 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-005577 · form4-02272024_110237.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 20, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 5,108 $22.64 $115,645.12
Disclosure

SEC source: 0001209191-23-056357 · doc4.xml · nonDerivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,486

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.5753 to $22.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 4,956 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-056357 · doc4.xml · derivative · entry 5

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,826

Underlying: Common Stock · 4,956 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 4,956 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-056357 · doc4.xml · derivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,826

Underlying: Common Stock · 4,956 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 4,956 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-056357 · doc4.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,594

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 4,956 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-056357 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
August 21, 2023 Filed Aug 23, 2023 23:31 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 10,000 $29.00 $289,970.00
Disclosure

SEC source: 0001209191-23-047125 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,682

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 to $29.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2023.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 00:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,893 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-036529 · doc4.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,893

Underlying: Common Stock · 1,893 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 00:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 974 $25.02 $24,369.48
Disclosure

SEC source: 0001209191-23-036529 · doc4.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,824

F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 00:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,893 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-036529 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 14,869 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-031243 · doc4.xml · derivative · entry 5

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,782

Underlying: Common Stock · 14,869 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 14,869 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-031243 · doc4.xml · derivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,782

Underlying: Common Stock · 14,869 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 15,310 $22.50 $344,475.00
Disclosure

SEC source: 0001209191-23-031243 · doc4.xml · nonDerivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,905

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 14,869 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-031243 · doc4.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,215

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 14,869 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-031243 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:15 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 27,259 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-027205 · doc4.xml · derivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,259

Underlying: Common Stock · 27,259 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:15 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 89,936 $0.00 Strike: $21.75 $0.00
Disclosure

SEC source: 0001209191-23-027205 · doc4.xml · derivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,936

Underlying: Common Stock · 89,936 shares

Expires 2033-05-01

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
April 06, 2023 Filed Apr 8, 2023 00:37 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,916 $18.16 $34,794.56
Disclosure

SEC source: 0001209191-23-023863 · doc4.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,477

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:37 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 5,275 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-023863 · doc4.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,826

Underlying: Common Stock · 5,275 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:37 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 5,275 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-023863 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 577 $18.78 $10,836.06
Disclosure

SEC source: 0001209191-23-013470 · doc4.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,118

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,353 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-013470 · doc4.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,706

Underlying: Common Stock · 1,353 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,353 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-013470 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
June 09, 2022 Filed Jun 11, 2022 00:51 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 653 $17.91 $11,694.90
Disclosure

SEC source: 0001209191-22-036176 · doc4.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,342

F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.91 to $18.449, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
June 08, 2022 Filed Jun 11, 2022 00:51 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,893 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-036176 · doc4.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,786

Underlying: Common Stock · 1,893 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.

F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.

Read SEC document
June 08, 2022 Filed Jun 11, 2022 00:51 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,893 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-036176 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 05, 2022 Filed Apr 7, 2022 22:49 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 21,101 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-023741 · doc4.xml · derivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,101

Underlying: Common Stock · 21,101 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2022 Filed Apr 7, 2022 22:49 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 72,414 $0.00 Strike: $25.75 $0.00
Disclosure

SEC source: 0001209191-22-023741 · doc4.xml · derivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,414

Underlying: Common Stock · 72,414 shares

Expires 2032-04-05

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:43 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,352 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-013281 · doc4.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,059

Underlying: Common Stock · 1,352 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:43 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 553 $23.80 $13,161.40
Disclosure

SEC source: 0001209191-22-013281 · doc4.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,102

F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:43 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,352 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-013281 · doc4.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.